^
    15d
    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (clinicaltrials.gov)
    P1/2, N=300, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    HRS-2189
    over1year
    Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    HRS-2189
    over1year
    Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    HRS-2189